We present a patient with a Philadelphia chromosome positive (Ph+) acute lymphocytic leukaemia (ALL) refractory to standard induction chemotherapy. Treatment with the ABL-specific tyrosine kinase inhibitor STI571 (Glivec, Gleevec, imatinib mesylate) resulted in a complete haematologic and cytogenetic remission. The Philadelphia chromosome, t(9;22), is found in about 5% of children with ALL but in 15-25% of adults with ALL. The t(9;22) translocation results in a fusion of the oncogene ABL on chromosome 9 with the BCR (breakpoint cluster region) on chromosome 22. The hybrid gene is expressed, with the gene product being a protein of p190 or p210 in size that has tyrosine kinase activity. The t(9;22) translocation with the deregulated tyrosine kinase activity of the BCR/ABL-fusion protein is known to be the causative molecular event in chronic myelogenous leukaemia (CML).
The Philadelphia chromosome, t(9;22), is found in about 5% of children with ALL but in 15-25% of adults with ALL. The t(9;22) translocation results in a fusion of the oncogene ABL on chromosome 9 with the BCR (breakpoint cluster region) on chromosome 22. The hybrid gene is expressed, with the gene product being a protein of p190 or p210 in size that has tyrosine kinase activity. The t(9;22) translocation with the deregulated tyrosine kinase activity of the BCR/ABL-fusion protein is known to be the causative molecular event in chronic myelogenous leukaemia (CML). 1 The presence of a t(9;22) translocation in ALL is associated with a poor prognosis and a high risk of relapse.
refractory Philadelphia chromosome positive (Ph+) ALL. Treatment with the novel ABL-specific tyrosine kinase inhibitor STI571 (Glivec, Gleevec, imatinib mesylate), a drug that has remarkable activity in CML, 3 resulted in a rapid clearance of the blast cells and an allogeneic stem cell transplantation procedure could be performed during complete remission of the leukaemia.
Case report
A 43-year-old female was referred to our hospital in January 2000 with a 1-month history of night sweats, weight loss and tiredness. The physical examination was unremarkable and there were no hepatosplenomegaly or palpable lymph nodes. The initial laboratory evaluation revealed haemoglobin 123 g/l, white cell count 100 ϫ 10 . On day 24 after start of the third chemotherapy course 80% blast cells persisted in the bone marrow. At this point she was, after informed written consent, enrolled in the STI571 expanded access program (STI571-114) for Ph+ and chemorefractory ALL. 4 STI571 was administered orally in a dose of 600 mg q.d. She was discharged from the hospital and the STI571 treatment was mainly given on an outpatient basis. She had no HLA-matched sibling and search for an unrelated donor was initiated. The STI571 treatment was well tolerated and only a slight and transient nausea was seen. Her overall wellbeing improved and blast cells cleared from her peripheral blood remarkably fast. After 14 days on STI571 she noticed that her night sweats had disappeared. A bone marrow smear, sampled 18 days after STI571 initiation, demonstrated a complete remission of the leukaemia, with no excess of blast cells; cytogenetically her bone marrow was negative for the t(9;22) translocation and the BCR/ABL fusion gene could not be detected using FISH on both metaphase and interphase cells. At this time, an optimally HLAmatched unrelated donor had been identified and the patient was scheduled for stem cell transplantation in the beginning of May 2001. The STI571 treatment was stopped 2 days prior to the conditioning treatment, which consisted of total body irradiation and cyclophosfamide (120 mg/kg body weight). The transplant was performed 50 days after start of STI571. Besides severe mucositis and neutropenic fever, the immediate post-transplantation period was uneventful. She had a stable platelet count above 50 ϫ 10 9 /l on day 14 and an absolute neutrophil count above 0.5 ϫ 10 9 /l on day 12 after the stem cell infusion. A moderate cutaneous graftversus-host disease (GVHD) developed, but was easily controlled by oral corticosteroid treatment. An asymptomatic CMV reactivation was detected using a PCR technique. Ganciclovir and later foscarnet treatment was given for 1 month. Minimal residual disease in the peripheral blood was followed monthly by qRT-PCR for the BCR/ABL fusion gene; after an initial increase 2 months after the transplant the number of transcripts decreased steadily over time until September 2001, when they became negative. Since then, she has been in molecular remission, ie negative for the BCR/ABL fusion gene using qRT-PCR. The reduction in BCR/ABL transcripts paralleled tapering of the cyclosporin A dose, which presumably enhanced the graftversus-leukaemia effect (GVL) of the donor T lymphocytes. Currently she is doing well apart from having a mild chronic GVHD, which is treated with cyclosporin A 25 mg b.i.d. and prednisone 5 mg q.d.. She was last seen at our outpatient clinic in August 2002. The plasma cyclosporin concentration and qRT-PCR results are presented in Figure 1 .
Discussion
Only a small minority of adults with ALL is currently cured. Results have improved modestly with more intensive post-remission chemotherapy. The performance of allogeneic stem cell transplantation in first remission is clearly effective in some individuals, eg those with Ph+ ALL, but it is unclear whether it is advantageous in most ALL patients.
The present case report, as well as most recent clinical studies of the ABL-specific tyrosine kinase inhibitor STI571, clearly demonstrates that in the majority of patients with CML in blast crisis and de novo Ph+ ALL, the leukaemic clone remains partially dependent on the BCR/ABL fusion gene for survival. In the study of Druker and co- worker 4 the overall response rate for STI571 therapy in patients with lymphoid blast crisis CML or Ph+ ALL was 70%, and 20% had complete remissions. However, all but one patient relapsed a median of 58 days after initiation of STI571 treatment. Thus, targeting a critical molecular abnormality, even in Ph+ acute leukaemia, is a useful strategy. Because of the short-lived remission induced by STI571 in Ph+ ALL, it appears that STI571 needs to be combined with other therapies to achieve an eradication of the disease. STI571 may be a useful bridge to transplantation in Ph+ ALL patients, since the outcome of haematopoietic stem cell transplantation is better in patients with acute leukaemia who are first returned to remission than in patients with fulminant disease. 5 Based on the short remission duration in STI571-treated Ph+ ALL patients, it appears that an allogeneic donor has to be identified and a transplant performed within 2 months after initiation of STI571.
Four months after the stem cell transplant our patient achieved a molecular remission, which has been stable since then. It has previously been shown that a qRT-PCR assay for the BCR/ABL transcript is a useful test for predicting CML patients at high risk of haemtologic relapse after allogeneic stem cell transplantation and may identify patients who might benefit from therapeutic interventions, eg donor lymphocyte infusions. 6 Similarly, the qRT-PCR assay for BCR/ABL transcripts appears even to predict relapse in patients with Ph+ ALL. 7, 8 Although the clinical value of qRT-PCR data after stem cell transplantation for CML has been questioned we have used this method at our center, to define relapse and to indicate the need for further treatment.
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